Digital is affecting all aspects of the pharmaceutical industry – from early discovery through commercialization, product modality, and uptake. But not all parts are being impacted to the same degree, as determined by changes in costs, productivity, or end products. Internal data systems and business processes are changing fast because they do not require regulatory oversight or depend on payer attitudes in the way new digital products do. Discovery teams are starting to use multiple new artificial intelligence (AI)-based tools, but the full results are not in yet.

This Datamonitor Healthcare report contains a Strategy module.